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Background. Vitiligo is a common skin disorder characterized by macular depigmentation of the skin. The etiopathogenesis
of the disease is still unclear, but there is evidence that autoimmunity and endocrine disfunction may be involved. Objective.
The aim of this study was to determine whether vitiligo is statistically associated with thyroid autoimmunity. Method.I na
prospective case-controlstudy, wecomparedthefrequency ofthyroidautoantibodies (thyroglobulinantibody, anti-Tgandthyroid
peroxidase antibody, and anti-TPO) in 33 patients with vitiligo and in 33 healthy volunteers. Thyroid autoantibodies and thyroid
hormones(thyroxine (T4), triiodothyronine (T3),and thyroid stimulatinghormone(TSH) were measured in allsubjects. Results.
Thyroid functional abnormalities were found in 6 (18.18%) patients. Anti-Tg and anti-TPO were positive in 9 (27.27%) and 8
(24.24%)patients, respectively. In control group, onlyonesubject (3.03%) had abnormalitiesinthyroid hormonalstatus,and two
subjects had positive thyroid autoantibodies. Compared with the control group, the frequency of both anti-Tg and anti-TPO was
signiﬁcantly higher in those with vitiligo (P<. 05). Conclusion. This study shows a signiﬁcant association between vitiligo and
thyroid autoimmunity, and that tests to detect thyroid autoantibodies are relevant in patients with vitiligo.
1.Introduction
Vitiligo is one of disorders of melanin pigmentation that
aﬀects approximately 0.5–2% of the population [1]. It is
characterized by macular depigmentation of varying sizes
or shapes with a tendency to progress. Depending on the
extent of the lesions, vitiligo can be classiﬁed into two
main categories: generalized and localized. Although the
pathogenesis of vitiligo is not yet fully understood, the
autoimmune hypothesis is the most commonly accepted.
This theory is supported by the clinical association of
vitiligo with autoimmune disorders, the frequent detection
of circulating autoantibodies to surface and cytoplasmatic
antigens of melanocytes [2, 3]. Furthermore, there are
ﬁndings of activated T cells in the periphery of actively
progressing lesions in some vitiligo patients [4]. Thyroid
functional disorders and autoimmune thyroid diseases have
been reported in association with vitiligo, and it seems that
the incidence of clinical and subclinical thyroid involvement
is more common in vitiligo patients than healthy subjects
[5, 6].
The aim ofthisstudy was todetermine whether vitiligois
statistically signiﬁcantly associated with thyroid autoimmu-
nity.
2.Patientsand Methods
The study included 33 patients with vitiligo, 19 female and
14 male, median age 42.39 (±13.66) years. Of them, there
were 14 (42.4%) patients with generalized vitiligo and 19
(57.6%) patients with localized form of disease. A detailed
history and examination were taken in all study subjects,
including patients age, age at onset, duration of disease,
associated diseases, history of thyroid disorders, and the
extent and severity of disease. The diagnosis of vitiligo was
made on clinical grounds. Skin biopsy was performed in
selected cases. The control group consisted of 33 volunteers,
19 female, and 14 male, median age 40.33 (±14.78) years.
Blood samples were taken and a physical examination and
thyroid sonography was performed. All subjects gave their
informed consentin accordancewith the requirementsofthe
institutional Ethichs Commitettee.2 Journal of Thyroid Research
Table 1: Demographic data of patients (Vitiligo group) and volun-
teers (Control group).
Vitiligo group
n (%)
Control group
n (%) P
Men, n (%) 19 (58) 19 (58)
Women, n (%) 14 (42) 14 (42)
Age range, years 16–64 17–69
Age, mean years
(SD) 42.39 (13.66) 40.33 (14.78) .558
Table 2: Clinical characteristics of patients with vitiligo.
Mean age of onset (SD) (year) 37.74 (12.45)
Age of onset range (year) 14–58
Mean duration (SD) (month) 55.85 (66.24)
Duration Range (month) 2–252
Type of vitiligo n,( % )
Generalized 14 (42)
Localized 19 (58)
Thyroid autoantibodies (thyroglobulin antibody, anti-
Tg and thyroid peroxidase antibody, anti-TPO) and thy-
roid hormones (thyroxine (T4), triiodthyronine (T3), and
thyroid stimulating hormone (TSH) were measured in
all subjects. Total T4 (normal range: 70–180nmol/L) and
total T3 (normal range 1.3–3.3nmol/L) were measured by
use of radioimmunoassay (RIA); TSH (normal range: 0.3–
4.2mLU/L) was determined by use of immunoradiomet-
ric assay (IRMA) (BRAHMS Aktiengesellschaft, Hennigs-
dorf, Germany). Serum levels of anti-Tg (threshold value:
115IU/mL)andanti-TPO(borderlinevalue:34IU/mL)were
measured by use of electrochemiluminescence immunoassay
(ECLIA) according to standard protocols (COBAS, Roche
Diagnostics GmbH, Germany). The upper limit of autoan-
tibody was determined by the laboratory.
Statistical comparisons were performed using χ2 test.
Data were considered statistically signiﬁcant at P<. 05.
3.Results
We performed a cross-sectional study in 33 consecutive
patients with vitiligo and 33 age- and sex-matched controls.
Demographic data of patients and controls are shown in
Table 1. The mean (SD) age of the patient and control
groups was 42.39 (±13.66) and 40.33 (±14.78), respectively
(P = .558). The duration of vitiligo ranged from 2 to 252
months. Fourteen patients had generalized, and nineteen
patients had localized vitiligo (Table 2). A family history
of thyroid diseases was recorded in 2 (6.06%) patients.
Thyroid functional abnormalities were found in 6 (18.18%)
patients. In the control group only one (3.03%) subject had
abnormalities in hormonal status. Hypoechogenic thyroid
tissue was seen in 2 (6.06%) patients. Goitre was diagnosed
in 4 (12.12%) patients with generalized vitiligo, from
which 3 (9.09%) of them had elevated levels of thyroid
autoantibodies and 2 (6.06%) had hormonal abnormalities.
The ultrasound examination of the thyroid gland in control
group was interpreted as normal in 32 (96.96%), and 1
(3.03%) volunteers had small simple goiter.
In patients with vitiligo anti-Tg titers were ranging from
11 to 1012IU/mL and anti-TPO antibody titers from 6 to
457IU/mL. In control group anti-Tg titers were ranging
from 10 to 153IU/mL, and anti-TPO antibody titers from
5.1 to 129IU/mL. Anti-Tg antibody in 9 (27.27%) patients,
anti-TPO antibody in 8 (24.24%) and both anti-Tg and
anti-TPO antibodies in 6 (18.18%) were higher than the
normal antibody titres. In the control group, one subject
(3.03%) had positive anti-Tg and one volunteer(3.03%)had
positive anti-TPO. The frequency of thyroid autoantibodies
was signiﬁcantly higher in vitiligo patients than in control
group (Table 3). Statistically signiﬁcant diﬀerence was also
found in values of anti-Tg and anti-TPO between patients
with generalized and patients with localized vitiligo (P<
.05).
A Chi-square test for independence (with Yates Conti-
nuity Correction) indicated signiﬁcant association between
higher values of anti-Tg (values more than 115IU/ml) and
vitiligo, χ2 (1,n = 66) = 5.775,P = .0163.
A Chi-square test for independence (with Yates Conti-
nuity Correction) indicated signiﬁcant association between
higher values of anti-TPO (values more than 34IU/ml) and
vitiligo, χ2 (1,n = 66) = 4.632,P = .0314.
4.Discussion
Vitiligo is an ancient disease that was known to Egyptians
even in the pre-Christian time [7]. Despite its long history,
our knowledge is actually limited. A number of genetic and
environmental factors have been implicated in the etiology
of vitiligo, but the mechanism of initiation of melanocyte
destruction and progression of disease is not yet clear [8].
Vitiligo has been reported in association with numerous
endocrine disorders. One of the main associations is with
thyroid abnormalities. It was already in 1941, when Robert
suggested that vitiligo might be connected with an increased
activity of the thyroid gland [9]. He noted a distinct rise of
the basal metabolism in 10 out 20 vitiligo patients tested.
Several authors reported a signiﬁcantly increased prevalence
of autoimmune thyroid disease in vitiligo patients; the rate
ofpositivity ofthyroid autoantibodies varied from 2.2% [10]
to 50% [11]. In addition, there is also a study reporting
a signiﬁcantly increased prevalence of vitiligo in patients
with autoimmune thyroid disease compared to patients with
nonautoimmune thyroid disease [5, 6].
In accordance to previous studies, we also demonstrated
that antithyroid autoantibodies were signiﬁcantly increased
in vitiligo patients in comparison to healthy subjects.
We detected elevated anti-Tg in 9 (27.27%) and elevated
anti-TPO in 8 (24.24%) of patients with vitiligo. Usually
about 10% of general population has positive antithyroid
antibodies; in this study the prevalence of autoantibod-
ies in control group is much lower than expected. The
diﬀerence it may partly be attributed to genetic factors.
Compared with the control group, the frequency of both
anti-Tg and anti-TPO antibodies was signiﬁcantly higherJournal of Thyroid Research 3
Table 3: Frequency of thyroid autoantibodies in the study group.
Anti-Tg (threshold value 115IU/mL) Anti-TPO (threshold value 34IU/mL)
Group Negative n (%) Positive n (%) Negative n (%) Positive n (%)
Vitiligo 24 (73) 9 (27) 25 (76) 8 (24)
Control 32 (97) 1 (3) 32 (97) 1 (3)
Total 56 (85) 10 (15) 57 (86) 9 (14)
Diﬀerence n (%) 8 (24) 7 (21)
χ2,Pχ 2 = 5.775,P = .0163 χ2 = 4.632,P = .0314
in those with vitiligo. Our results are consistent with a
clinical study performed by Sedighe and Gholamhossein
[12]. They analyzed antithyroid antibodies in 109 Iranian
patients with vitiligo and found that anti-TPO and anti-
Tg antibody were positive in 40 (36.7%) and 35 (32.1%)
cases, respectively. Daneshpazhooh and colleagues measured
only the serum level of anti-TPO antibody and reported
signiﬁcantly high levels in vitiligo patients compared to
healthy controls [13]. In study that was carried out in India,
the anti-TPO antibody was positive in 31.4% cases [14].
Our ﬁndings showed that the frequency of anti-TPO was
more signiﬁcant than anti-Tg. This antibody, historically
referred to as the antimicrosomal antibody, is established
as a sensitive tool for the detection of early subclinical
autoimmune thyroid diseases and identiﬁcation of at-risk
cases for autoimmune thyroid diseases [15]. Nordyke et al.
reported that anti-TPO antibody tends to havemore correla-
tionwiththyroiddysfunctionthandoestheanti-Tgantibody
[16].
Vitiligo frequently precedes the thyroid involvement,
thus screening vitiligo patients for thyroid antibody seems
plausible [17].
5.Conclusion
The study revealed a signiﬁcant association between vitiligo
and thyroid autoimmunity and showed the tests used to
detect thyroid autoantibodies to be relevant in patients with
vitiligo. Vitiligo oﬀers many beneﬁts as a model for the
study of autoimmunity, in that it can be used to identify the
contributing roles of immunogenetics and endocrine factors
in the initiation and propagation of autoimmune disease.
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